ShedRx vs Yucca Health (2026): prices, structure, verdict

On tirzepatide, Yucca Health↗ is cheaper: $258 versus $289 a month all-in — a $31 monthly gap, $372 across a year of maintenance dosing, and Yucca Health's figure is dose-flat while ShedRx↗'s structure is not.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Yucca Health is cheaper: $146 versus $249 a month all-in — a $103 monthly gap, $1,236 across a year of maintenance dosing, and Yucca Health's figure is dose-flat while ShedRx's structure is not.

§ Side by side

§ Each record, read aloud

The two records, condensed

ShedRx: the record, condensed

Start with the load-bearing figure: $289 a month, all-in, is what ShedRx charges for tirzepatide at the 10 mg basis. Pricing steps with the dose here: from $199 at entry to $289 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $1,080 a year, which is why every ranking on this site uses the larger number.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes ShedRx unusually easy to compare and unusually easy to leave.

To place the number: #5 of 17 verified programs, with the floor $74/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

On semaglutide, the number that matters at ShedRx is $249 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Pricing steps with the dose here: from $175 at entry to $249 at the 2.4 mg basis. Multiply the wrong one of those by twelve and your budget is off by $888 a year, which is why every ranking on this site uses the larger number.

There is no membership line. $249 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 20 in the verified semaglutide index — $116/month above the floor (Oak Longevity, $133) — and sits $100 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,988.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

Yucca Health: the record, condensed

Yucca Health’s tirzepatide program bills $258 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Yucca Health is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $258 is the whole subscription, which makes Yucca Health unusually easy to compare and unusually easy to leave.

To place the number: #2 of 17 verified programs, with the floor $43/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $191 a month. A year at this figure: $3,096 monthly-billed.

Start with the load-bearing figure: $146 a month, all-in, is what Yucca Health charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $146 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #2 of 20 in the verified semaglutide index — $13/month above the floor (Oak Longevity, $133) — and sits $203 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $1,752.

Operationally at Yucca Health: shipping included; commitment 6-month term; cancellation 6-month term applies; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Yucca Health page · visit Yucca Health ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Yucca Health at $258, ShedRx at $289 — a $31 monthly spread that compounds to $372 over a maintenance year and $744 over two.

Structure sharpens the gap: Yucca Health’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while ShedRx’s is not — so Yucca Health’s number is a ceiling and ShedRx’s advertised entry ($199) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $146 (Yucca Health) against $249 (ShedRx). $103 a month sounds survivable; $1,236 a year is a decision.

Structure sharpens the gap: Yucca Health’s figure is dose-flat (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill the same), while ShedRx’s is not — so Yucca Health’s number is a ceiling and ShedRx’s advertised entry ($175) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

A way to feel the $31 monthly gap: over a year it funds 1.4 extra months at Yucca Health’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $744, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: ShedRx $289/mo month-to-month against Yucca Health $258/mo month-to-month. The order holds: Yucca Health leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: ShedRx $867 monthly; Yucca Health $774 monthly — best path favors Yucca Health by $93. 6 months: ShedRx $1,734 monthly; Yucca Health $1,548 monthly — best path favors Yucca Health by $186. 12 months: ShedRx $3,468 monthly; Yucca Health $3,096 monthly — best path favors Yucca Health by $372. 24 months: ShedRx $6,936 monthly; Yucca Health $6,192 monthly — best path favors Yucca Health by $744.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: ShedRx $747 vs Yucca Health $438 — $309 to Yucca Health. 6 mo: ShedRx $1,494 vs Yucca Health $876 — $618 to Yucca Health. 12 mo: ShedRx $2,988 vs Yucca Health $1,752 — $1,236 to Yucca Health. 24 mo: ShedRx $5,976 vs Yucca Health $3,504 — $2,472 to Yucca Health.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: ShedRx publishes “not published”; Yucca Health publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: ShedRx — none month-to-month; 72-hour notice before the next billing cycle. Yucca Health — 6-month term; 6-month term applies.

Evidence: ShedRx source-verified (captured 2026-08-05); Yucca Health source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #5 and #2 of 17: between them lie 2 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #13 and #2 of 20: between them lie 10 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between ShedRx and Yucca Health

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (ShedRx: 72-hour notice before the next billing cycle; Yucca Health: 6-month term applies) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings